Let's talk more about DoveTree LLC. AI is so useful.

$XTALPI(02228.HK) Direct to the results:

1 | The True Origins and Industry Position of DoveTree LLC

Dimension	Current Status	Remarks
Establishment	2024 Q4, registered as an LLC in Massachusetts	State business records; first public appearance was in the collaboration announcement with XtalPi Holdings on 2025-06-23 (prnewswire.com)
Positioning	Verdine Innovation Studio—Incubating novel mechanism therapies for oncology, autoimmune, and neurological diseases by integrating founder Gregory Verdine's scientific/capital network	Similar to "platform incubators" like FogPharma but more focused on target selection + early-stage architecture design
Founder	Gregory L. Verdine Ph.D.• Tenured Professor of Chemistry at Harvard University (Erving Chair)• Founded/co-founded >10 biotech companies, including Enanta, Wave, Aileron, etc., with ≥5 listed on U.S. markets• Directly associated with 3 FDA-approved drugs (romidepsin, paritaprevir, maviret series)• Since 2022, also an investment partner at Andreessen Horowitz (a16z) Bio & Health (hscrb.harvard.edu, ainvest.com)
Funding/Shareholders	No independent financing rounds disclosed yet; a16z and Verdine's VC vehicles (Larkspur, LifeMine SPV, etc.) are seen as potential cornerstones	Industry reports (biospectrumasia.com)
Pipeline	As of 2025-06, no proprietary IND projects; opted to collaborate with external AI-Physics platforms to rapidly fill the pipeline via "agreements + milestones"	The contract with XtalPi is the first publicly announced project

Industry Position Summary: DoveTree itself is still in the "company-builder/project shell" phase, lacking traditional R&D capabilities; its influence stems from Verdine's academic reputation + serial entrepreneurial success, as well as a16z's robust financing/BD channels. This is believed to be sufficient for early-stage innovation projects to quickly secure funding and resources, but DoveTree still relies on external technology platforms (e.g., XtalPi) for heavy experimental work.

2 | The Long-Term Implications of the Announcement Terms for XtalPi (02228)

Dimension	Details (from the Announcement)	Long-Term Value	Risk Factors
Immediate Cash Flow	Upfront payment of $100 million ($51 million within 10 days + $49 million within 180 days) (prnewswire.com)	Equivalent to 1.3× XtalPi's 2023 annual revenue → Can support subsequent robotics lab expansion and overseas BD	The contract is still a non-binding term-sheet; delays or reductions in the final agreement could impact recognition
Milestones & Royalties	Development + sales milestones capped at "billions of dollars" + single-digit sales royalties	If 1-2 pipelines reach late-stage, XtalPi could generate high-leverage royalty streams, significantly boosting valuation flexibility	AI early hit→clinical success rate <8%; high-value milestones are often unmet
Technical Validation	Projects include both small molecules and antibodies	First time XtalPi's AI + robotics capabilities extend to antibody discovery; successful delivery could correct the perception of "only excelling in small molecules"	Antibody workflows demand higher wet-lab and CMC requirements, increasing delivery pressure
North American Channels	Verdine + a16z endorsement	Establishes a "trust bridge" for XtalPi in the Boston-Cambridge biotech circle, facilitating more U.S.-based BD contracts	Profitability still depends on actual delivery to solidify reputation
Valuation Anchor	Comparable in upfront payment scale to AI-Big Pharma frameworks like Recursion-Roche and Exscientia-Sanofi	Boosts the "platform-type AI Drug-Discovery" valuation multiple in the Hong Kong secondary market; a strong bargaining chip for future U.S. or STAR Market refinancing	Limited liquidity in Hong Kong; realizing valuation requires sustained performance

3 | Scenario Analysis

Optimistic Path
2025-2027: First batch of targets yields leads within 18 months; DoveTree completes Series A+B, XtalPi receives 1-2 early milestone payments; 2028-2029 sees 1 IND enter Phase I → XtalPi confirms ≥$300 million in development milestones → Stock price and revenue rise.

Baseline Path
After upfront payment, earliest milestones take 24-30 months; if key drugability metrics are unmet, milestones are delayed, limiting discounted future revenue impact. However, technical validation can still be leveraged for next-client BD.

Pessimistic Path
DoveTree postpones Definitive Agreement due to financing market shifts or weak asset performance → Project termination; XtalPi may need to refund partial payments or only recognize break-up fees, dampening market sentiment.

Conclusion

DoveTree LLC → Not a traditional pharma giant but a "project incubator + investment" platform newly built by Gregory Verdine with a16z resources; influence primarily derives from the founder's academic and entrepreneurial reputation.

For XtalPi, this term-sheet carries triple significance: major cash infusion + brand endorsement + technical expansion validation. If executed smoothly, it could elevate XtalPi from an "AI small-molecule service provider" to an industry benchmark for "multi-modal AI-robotics drug factories." However, the deal has yet to be finalized, clinical milestones have long cycles, and execution/financing uncertainties require ongoing attention.